Industry News
Natural products targeted for potential drugs
Natural products provide a validated basis for protein-drug interactions that should be exploited as a tool for rational drug design, Griffith University's Prof Ron Quinn told delegates at the Australian Health and Medical Research Congress last week. [ + ]
Learning about liver tissue
A group of Australian researchers are pursuing ground-breaking work on receptors in muscle tissue which play an unexpectedly important part in regulating cholesterol levels. [ + ]
European research program thrown open to Aussies
Australian researchers have the opportunity to participate in the Sixth Framework Program for European Research and Technological Development (FP6), but they should think hard about the value they can bring to collaborative projects and be prepared to come with their own funding, according to presenters at a special symposium held by the Australasian Research Management Society at the Australian Health and Medical Research Congress (AHMRC) last week. [ + ]
Bionomics hails new class of epilepsy drug
An Australian research study published this week in the prestigious journal Proceedings of the National Academy of Science explains why current drugs don't work on a common, inherited form of epilepsy -- and points the way to a new class of epilepsy therapeutics. [ + ]
Taking Australian biotechnology to the world
Australian Biotechnology News and Factiva, a Dow Jones and Reuters Company, concluded an agreement this week that will see ABN's content distributed globally to over 1.5 million desktops. [ + ]
Shareholder contact pays off for Meditech
An innovative approach in reaching out to shareholders has raised $AU3 million for Melbourne-based biotech company Meditech Research. [ + ]
Australian HIV vaccine trial touted for 2003
A public consortium of researchers is hoping to get permission to start a Phase I clinical trial of a new HIV vaccine early in the new year. [ + ]
Peptech MD moves to sweeten $8.9m loss
Peptech managing director Stephen Kwik is accentuating the positives after Peptech reported an after-tax loss of $AU8.9 million loss in the 12 months to September, after a $AU32.7 million net profit in the previous year. [ + ]
Genetic Technologies chief defends Myriad deal
Genetic Technologies' executive chairman Dr Mervyn Jacobson is surprised and disappointed by recent criticism of the deal he brokered with US genetic testing giant Myriad Genetics. [ + ]
Nanomaterial could revolutionise molecular sensing
Researchers from Monash University and the University of Sydney have designed a material containing holes one millionth of a millimetre wide that could provide a new mechanism for sensing molecules.
[ + ]PanVax collaborates with the Institute Pasteur
Prima BioMed subsidiary PanVax has entered into a research collaboration with the Institute Pasteur in France. [ + ]
Researchers get closer to malaria vaccine
The hunt for an anti-malaria vaccine is hotting up thanks to Australian researchers who have shown for the first time that T-cells can provide cell-based immunity in humans against the red blood cell stage of malaria. [ + ]
Antisense Therapeutics placement beats expectations
Antisense Therapeutics has raised $500,000 over its expected $4 million in an oversubscribed share placement that closed two days earlier than originally planned. [ + ]
Khan resumes Biota board campaign
The majority shareholder in Biota Holdings, Perth lawyer Farooq Khan, has resumed his campaign to force his way onto the listed biotech's board. [ + ]
UNSW rolls out health research network
A research network to provide GPs and other primary health care practitioners with support, mentoring and workshops to develop their research ideas is being rolled out around New South Wales.
[ + ]